Related references
Note: Only part of the references are listed.Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia
Alessandro M. Vannucchi et al.
BLOOD (2008)
MPL mutations in myeloproliferative disorders:: analysis of the PT-1 cohort
Philip A. Beer et al.
BLOOD (2008)
Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes
Bridget S. Wilkins et al.
BLOOD (2008)
Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment
Magnus Hultdin et al.
MEDICAL ONCOLOGY (2007)
Mechanisms of disease: The myeloproliferative disorders
Peter J. Campbell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
MPL515 mutations in myeloproliferative and other myeloid disorders:: a study of 1182 patients
Animesh D. Pardanani et al.
BLOOD (2006)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status:: a prospective study
PJ Campbell et al.
LANCET (2005)
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia
RL Levine et al.
BLOOD (2005)
JAK2V617F mutation in essential thrombocythaemia:: clinical associations and long-term prognostic relevance
AP Wolanskyj et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Clinical implications of the JAK2 V617F mutation in essential thrombocythemia
E Antonioli et al.
LEUKEMIA (2005)
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia
CN Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Long-term use of anagrelide in young patients with essential thrombocythemia
EC Storen et al.
BLOOD (2001)